Allogene Therapeutics, Inc. - ALLO
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Feb 17, 2026 | SCHEDULE 13G/A | Arie Belldegrun, M.D. | 5.8% | 13,248,170 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Bellco Legacy LLC | 0.2% | 539,867 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Bellco Legacy IV LLC | 2.1% | 4,710,120 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Vida Ventures LLC | 0.8% | 1,798,163 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Vida Ventures III, L.P. | 0.8% | 1,720,172 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Vida Ventures III-A, L.P. | 0.0% | 3,965 | View |
| Feb 13, 2026 | SCHEDULE 13G | David D. Chang, M.D., Ph.D. | 5.2% | 12,101,223 | View |
| Feb 13, 2026 | SCHEDULE 13G | Chang 2006 Family Trust | 0.5% | 1,201,108 | View |
| Feb 13, 2026 | SCHEDULE 13G | JEC 2019 Trust | 0.4% | 856,044 | View |
| Feb 13, 2026 | SCHEDULE 13G | RTC 2019 Trust | 0.4% | 856,044 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Arie Belldegrun, M.D. | 5.6% | 12,668,344 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Bellco Legacy LLC | 0.2% | 539,867 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Bellco Legacy IV LLC | 2.1% | 4,710,120 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Vida Ventures LLC | 0.8% | 1,798,163 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Vida Ventures III, L.P. | 0.8% | 1,720,172 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Vida Ventures III-A, L.P. | 0.0% | 3,965 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Capital World Investors | 0.0% | 0 | View |
| Nov 12, 2025 | SCHEDULE 13G/A | David D. Chang, M.D., Ph.D. | 4.9% | 11,234,918 | View |
| Nov 12, 2025 | SCHEDULE 13G/A | Chang 2006 Family Trust | 0.5% | 1,201,108 | View |
| Nov 12, 2025 | SCHEDULE 13G/A | JEC 2019 Trust | 0.4% | 856,044 | View |
| Nov 12, 2025 | SCHEDULE 13G/A | RTC 2019 Trust | 0.4% | 856,044 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.